A Phase I-II trial of the combination of recombinant leukocyte A interferon and recombinant human interferon-γ in patients with metastatic malignant melanoma

E. T. Creagan, Charles Lawrence Loprinzi, D. L. Ahmann, Daniel J Schaid

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Twenty patients with advanced malignant melanoma received daily intramuscular recombinant leukocyte A interferon (rIFN-αA, Roferon-A, Hoffmann-Laroche, Nutley, NJ) concomitant with recombinant human interferon-γ (rIFN-γ Genentech, South San Francisco, CA). During the first week α dose was 2 x 106 U/m2 and the γ dose was 0.01 mg/m2 with escalations, if clinically tolerable, during the second week to 5 x 106 U/m2 and 0.025 mg/m2, respectively. Twelve patients received the escalated doses; subsequent granulocytopenia and a flu-type illness were severe in four of the 12. We observed one partial response of MRI-documented and biopsy-confirmed osseous metastases for 7+ months. For all study participants, the median time to progression was 1 month with a median survival of 6 months. From the dose and schedule which we utilized, concurrent rIFN-αA and rIFN-γ provided little impact on advanced malignant melanoma.

Original languageEnglish (US)
Pages (from-to)2472-2474
Number of pages3
JournalCancer
Volume62
Issue number12
StatePublished - 1988

Fingerprint

Interferon-alpha
Interferons
Melanoma
Agranulocytosis
San Francisco
Appointments and Schedules
Neoplasm Metastasis
Biopsy
Survival
interferon alfa-2a

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{b61b1930085148e59e507f6aaa1e38b3,
title = "A Phase I-II trial of the combination of recombinant leukocyte A interferon and recombinant human interferon-γ in patients with metastatic malignant melanoma",
abstract = "Twenty patients with advanced malignant melanoma received daily intramuscular recombinant leukocyte A interferon (rIFN-αA, Roferon-A, Hoffmann-Laroche, Nutley, NJ) concomitant with recombinant human interferon-γ (rIFN-γ Genentech, South San Francisco, CA). During the first week α dose was 2 x 106 U/m2 and the γ dose was 0.01 mg/m2 with escalations, if clinically tolerable, during the second week to 5 x 106 U/m2 and 0.025 mg/m2, respectively. Twelve patients received the escalated doses; subsequent granulocytopenia and a flu-type illness were severe in four of the 12. We observed one partial response of MRI-documented and biopsy-confirmed osseous metastases for 7+ months. For all study participants, the median time to progression was 1 month with a median survival of 6 months. From the dose and schedule which we utilized, concurrent rIFN-αA and rIFN-γ provided little impact on advanced malignant melanoma.",
author = "Creagan, {E. T.} and Loprinzi, {Charles Lawrence} and Ahmann, {D. L.} and Schaid, {Daniel J}",
year = "1988",
language = "English (US)",
volume = "62",
pages = "2472--2474",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - A Phase I-II trial of the combination of recombinant leukocyte A interferon and recombinant human interferon-γ in patients with metastatic malignant melanoma

AU - Creagan, E. T.

AU - Loprinzi, Charles Lawrence

AU - Ahmann, D. L.

AU - Schaid, Daniel J

PY - 1988

Y1 - 1988

N2 - Twenty patients with advanced malignant melanoma received daily intramuscular recombinant leukocyte A interferon (rIFN-αA, Roferon-A, Hoffmann-Laroche, Nutley, NJ) concomitant with recombinant human interferon-γ (rIFN-γ Genentech, South San Francisco, CA). During the first week α dose was 2 x 106 U/m2 and the γ dose was 0.01 mg/m2 with escalations, if clinically tolerable, during the second week to 5 x 106 U/m2 and 0.025 mg/m2, respectively. Twelve patients received the escalated doses; subsequent granulocytopenia and a flu-type illness were severe in four of the 12. We observed one partial response of MRI-documented and biopsy-confirmed osseous metastases for 7+ months. For all study participants, the median time to progression was 1 month with a median survival of 6 months. From the dose and schedule which we utilized, concurrent rIFN-αA and rIFN-γ provided little impact on advanced malignant melanoma.

AB - Twenty patients with advanced malignant melanoma received daily intramuscular recombinant leukocyte A interferon (rIFN-αA, Roferon-A, Hoffmann-Laroche, Nutley, NJ) concomitant with recombinant human interferon-γ (rIFN-γ Genentech, South San Francisco, CA). During the first week α dose was 2 x 106 U/m2 and the γ dose was 0.01 mg/m2 with escalations, if clinically tolerable, during the second week to 5 x 106 U/m2 and 0.025 mg/m2, respectively. Twelve patients received the escalated doses; subsequent granulocytopenia and a flu-type illness were severe in four of the 12. We observed one partial response of MRI-documented and biopsy-confirmed osseous metastases for 7+ months. For all study participants, the median time to progression was 1 month with a median survival of 6 months. From the dose and schedule which we utilized, concurrent rIFN-αA and rIFN-γ provided little impact on advanced malignant melanoma.

UR - http://www.scopus.com/inward/record.url?scp=0024203369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024203369&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 2472

EP - 2474

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -